FDA Reassesses Safety of Mifepristone, the Abortion Medication
The FDA is reviewing the safety of mifepristone, a widely used medication for abortion, amid concerns raised by conservative groups and recent data. This ongoing assessment could impact access and prescribing practices.
The U.S. Food and Drug Administration (FDA) has announced it is conducting a comprehensive review of the safety profile of mifepristone, a medication widely used in abortion procedures for the past 25 years. This review comes amid increasing scrutiny from conservative state attorneys general and anti-abortion groups. The initiative was initiated through a letter from Health and Human Services Secretary Robert F. Kennedy Jr., as reported by CBS News.
The focus of the review is on whether current practices align with FDA safety standards that ensure a drug's benefits outweigh its risks. The agency plans to evaluate the latest data, real-world outcomes, and evidence concerning the drug's safety and effectiveness. This step follows recent regulatory changes by the Biden administration, which in 2023 allowed patients to access mifepristone via mail and telehealth consultations, a move criticized by some conservative voices.
The decision to review the drug was influenced by a study from the Ethics and Public Policy Center (EPPC), which raised concerns about potential dangers when mifepristone is provided without adequate medical support or supervision. The study referenced FDA data indicating 2,740 adverse events from 2000 to 2012, including 416 cases requiring blood transfusions. The EPPC estimates that nearly 11% of women experience serious adverse effects, though other sources dispute this figure.
Medical experts, including CBS News contributor Dr. Céline Gounder, suggest the actual rate of serious complications is likely much lower, possibly less than 1 in 200 cases. Advocates for continued use of mifepristone emphasize its proven safety record, citing over 100 studies and the fact that more than 7.5 million women have used the drug since its FDA approval in 2000. It remains approved for use up to 10 weeks of gestation.
While the review could result in modifications to how the drug is prescribed—such as restricting its availability through telehealth or limiting the types of providers authorized to dispense it—experts believe a complete ban or withdrawal of approval is improbable. Dr. Gounder noted that such a move would be extraordinary and likely face immediate legal challenges.
Although no specific timeline has been provided for the completion of this review, Kennedy assured that the FDA would keep states informed as the process advances. The outcome of this investigation could influence future policies regarding medication abortion access in the United States.
For more information, the U.S. National Library of Medicine provides details about mifepristone at https://medlineplus.gov/druginfo/meds/a600042/.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Child Health Report Omits Gun Violence as Leading Cause of Child Mortality
A new child health strategy overlooks gun violence, the leading cause of death among young people, raising concerns among experts about policy gaps and the importance of firearm safety.
U.S. Government Considers Linking Tylenol to Autism Risks
The Trump administration is considering linking acetaminophen, the active ingredient in Tylenol, to autism risk and advising pregnant women to avoid its use unless necessary. This move reflects ongoing debates about medication safety during pregnancy.
FDA Grants Breakthrough Status to AI-Driven Breast Cancer Risk Assessment Tool
A novel AI-powered mammogram analysis tool from Washington University has received FDA breakthrough status, promising more accurate five-year breast cancer risk predictions to improve early detection and prevention.
Brain Imaging Shows Action-Based Brain Organization in Individuals Without Hands
New neuroimaging research reveals that the brain is organized around actions like tool use, rather than specific body parts, demonstrating remarkable neural plasticity even in individuals born without hands.